Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis☆☆☆★★★

Abdelaziz, Muntasir M.; Devalia, Jagdish L.; Khair, Omer; Bayram, Hasan; Prior, Andrew; Davies, Robert J.

doi:10.1016/s0091-6749(98)70256-8

Cited by 103 publications

(73 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20,22,33 The effect of fexofenadine on nasal congestion might reflect an activity that is broader than its antagonism at the H 1 -receptor. Numerous in vitro studies with fexofenadine have highlighted the potential of this agent to produce significant anti-inflammatory effects at clinically relevant concentrations, [34][35][36][37][38] and it is hypothesized that these effects might contribute to inhibition of the late-phase response. 37 In this large pediatric population, the incidence and severity of reported adverse events with fexofenadine were similar to those for placebo.…”

Section: Discussionmentioning

confidence: 99%

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

Wahn¹,

Meltzer²,

Finn³

et al. 2003

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Background: This is the first prospective, randomized, doubleblind, placebo-controlled study showing statistical improvement of an H 1 -antihistamine in children with seasonal allergic rhinitis in all symptoms throughout the entire treatment period. Objective: This randomized, placebo-controlled, parallelgroup, double-blind study was performed to assess the efficacy and safety of fexofenadine in children with seasonal allergic rhinitis. Methods: This study was conducted at 148 centers in 15 countries. Nine hundred thirty-five children (aged 6-11 years) were randomized and treated with either fexofenadine HCl 30 mg (n = 464) or placebo (n = 471) tablets twice a day for 14 days. Individual symptoms (sneezing; rhinorrhea; itchy nose, mouth, throat, and/or ears; itchy, watery, and/or red eyes; and nasal congestion) were assessed at baseline and then daily at 7:00 AM and 7:00 PM (±1 hour) during the double-blind treatment period. Each total symptom score was the sum of all symptoms, excluding nasal congestion. The primary efficacy variable was the change from baseline in the average of the daily 12-hour evening reflective total symptom scores throughout the double-blind treatment. Safety was evaluated from adverse-event reporting, vital signs, physical examinations, and clinical laboratory data at screening and study end point.Results: Fexofenadine was significantly superior to placebo in the primary efficacy analysis (P ≤ .0001). Individual symptom scores showed statistically significant superiority compared with placebo (P < .05), including nasal congestion in the evening reflective assessment (P < .05). There was no significant difference in adverse events between fexofenadine and placebo, either overall or by causality.

show abstract

Section: Discussionmentioning

confidence: 99%

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

Wahn¹,

Meltzer²,

Finn³

et al. 2003

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…1, D-F -There are four H-subtype cell surface GPCRs that can mediate cellular response to histamine. Because H 1 receptors are functionally more dominant in endothelium (9), diphenhydramine (6,21), and fexofenadine (53,54), two specific H 1 receptor antagonists, were applied to evaluate whether H 1 receptors are responsible for the histamineevoked mobilization of intracellular Ca 2ϩ in HUVECs. As expected, 40 min preincubation with either diphenhydramine (30 M) or fexofenadine (30 M) prevented both histaminetriggered store release (Fig.…”

Section: Rna Isolation and Reverse Transcription Polymerase Chain Reamentioning

confidence: 99%

Stromal Interaction Molecule 1 (STIM1) and Orai1 Mediate Histamine-evoked Calcium Entry and Nuclear Factor of Activated T-cells (NFAT) Signaling in Human Umbilical Vein Endothelial Cells

Zhou

Zheng

et al. 2014

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: Histamine is a major inflammatory mediator. Results: H 1 receptor, STIM1, Orai1, and extracellular calcium are indispensable for histamine-induced intracellular calcium mobilization, NFAT nuclear translocation, and IL-8 production in HUVECs. Conclusion: STIM1 and Orai1 mediate histamine-evoked calcium entry and NFAT signaling in endothelial cells. Significance: STIM1 and Orai1 are essential for histamine-induced inflammatory signaling of endothelial cells.

show abstract

“…Their additional anti-inflammatory effect in nasal allergic inflammation has emerged in a number of studies: in children terfenadine [38] and cetirizine [39] reduced inflammatory cell infiltrate and intercellular adhesion molecule (ICAM)-1 expression on nasal epithelial cells, fexofenadine modulated the expression of leukocyte function-associated antigen (LFA)-1 and ICAM-1 on eosinophils [40], induced eosinophil-apoptosis [40] and attenuated eosinophil-mediated release of IL-8, granulocyte-macrophage colonystimulating factor (GM-CSF), and soluble ICAM-1 from nasal epithelial cells [41]. Although histamine is a proven asthma mediator, H 1 -antihistamines have rather inconsistent effects in asthma challenge models, BHR, and symptoms of perennial and seasonal asthma.…”

Section: Pharmacotherapymentioning

confidence: 99%

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

et al. 2013

View full text Add to dashboard Cite

The strong epidemiologic and pathophysiologic link between allergic rhinitis (AR) and asthma has led to the concept of 'united airways disease' or 'respiratory allergy', implying that allergy, in its widest sense, underlies this clinical syndrome. Progression from AR to asthma is frequent and part of the 'atopic march'. Since pediatric immune responses are more adaptable and therefore may be more amenable to treatment, interventions at early childhood are characterized by a higher chance to affect the natural history of respiratory allergy. Although current treatments are quite effective in alleviating respiratory allergy symptoms, it has proven much more difficult to confirm any influence on the progression of the disease. Much more promising is the field of specific allergen immunotherapy, where current evidence, although not yet of ideal robustness, points towards a disease-modifying effect. In addition, newer or emerging, possibly more effective or more targeted interventions are promising in the preventive sense.

show abstract

Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis☆☆☆★★★

Cited by 103 publications

References 49 publications

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

Stromal Interaction Molecule 1 (STIM1) and Orai1 Mediate Histamine-evoked Calcium Entry and Nuclear Factor of Activated T-cells (NFAT) Signaling in Human Umbilical Vein Endothelial Cells

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

Contact Info

Product

Resources

About